IP Verse

Dry Powder Inhalation Drug Products Exhibiting Moisture Control Properties And Methods Of Administering The Same

Patent No. EP3461474 (titled "Dry Powder Inhalation Drug Products Exhibiting Moisture Control Properties And Methods Of Administering The Same") was filed by Glaxosmithkline on Aug 31, 2011. The application was issued on Nov 11, 2020.

Patent Summary

Dry powder inhalation device that can be used for treatment of pulmonary and systemic diseases. The device includes a pharmaceutical composition present therein, the pharmaceutical composition comprising a compound which is (6, 11, 16, 17)-6,9-difluoro-17-[(fluoromethyl)thio]carbonyl-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl 2- furancarboxylate or a solvate thereof.

Patent Family

Patent Family

Patent Oppositions (6)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GENERICS UKAug 11, 2021FRKELLY
HGFAug 9, 2021HGF
TEVA UKJul 13, 2021ELKINGTON AND FIFE
TEVA PHARMACEUTICALSJul 13, 2021ELKINGTON AND FIFE
SANDOZJun 25, 2021MAIWALD
SANDOZJun 25, 2021MAIWALD PATENT UND RECHTSANWALTSGESELLSCHAFT

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3461474

GLAXOSMITHKLINE
Application Number
EP18201769A
Filing Date
Aug 31, 2011
Status
Revoked
May 27, 2022
Publication Date
Nov 11, 2020
External Links
Slate, Register , Google Patents